Characterization of the interface between composites and embedded Fiber Optic sensors or NiTiNOL wires

n/

Prospective Improvements for Safer Fuel Tanks: Experimental Tests

In past studies, some of the authors presented how the integration of different systems, for the prevention of fires or explosions due to impact or bullet damage, may significantly improve the safety of fuel tanks. Leakage, after bullet penetration or debris impact, can be significantly reduced by introducing polymeric materials with self-healing capabilities for the container’s walls, while an internal aluminium filler can reduce the sloshing and the danger of fuel ignition. In the present paper, an experimental evaluation of the proposed solution is presented. A ballistic test campaign on a fluid container was performed to investigate the interaction between an ethylene–methacrylic acid (EMAA)-based ionomeric wall (i.e. Dupont®Surlyn 8940) and an internal aluminium filler (i.e. Explosafe®). Results show that the presence of the fluid increases the self-healing capabilities, which are however slightly affected by the internal aluminium filler; the contribution in terms of sloshing reduction remains relevant. Moreover, additional configurations based on multilayer panels are presented. The authors studied the healing process of EMAA in a sandwich configuration made of one skin of ionomer and one skin of carbon fibre, sepa- rated by an aramidic honeycomb. The main objective of the honeycomb is to prevent the remarkable reduction of the healing capabilities observed when ionomer is directly coupled to aramidic fabric or composite panels. The new multilayer configurations have been tested at different impact conditions

Comparison of tolerability and adverse symptoms in oxcarbazepine and carbamazepine in the treatment of trigeminal neuralgia and neuralgiform headaches using the Liverpool Adverse Events Profile (AEP)

Background Adverse effects of drugs are poorly reported in the literature . The aim of this study was to examine the frequency of the adverse events of antiepileptic drugs (AEDs), in particular carbamazepine (CBZ) and oxcarbazepine (OXC) in patients with neuralgiform pain using the psychometrically tested Liverpool Adverse Events Profile (AEP) and provide clinicians with guidance as to when to change management. Methods The study was conducted as a clinical prospective observational exploratory survey of 161 patients with idiopathic trigeminal neuralgia and its variants of whom 79 were on montherapy who attended a specialist clinic in a London teaching hospital over a period of 2 years. At each consultation they completed the AEP questionnaire which provides scores of 19–76 with toxic levels being considered as scores >45. Results The most common significant side effects were: tiredness 31.3 %, sleepiness 18.2 %, memory problems 22.7 %, disturbed sleep 14.1 %, difficulty concentrating and unsteadiness 11.6 %. Females reported significantly more side effects than males. Potential toxic dose for females is approximately 1200 mg of OXC and 800 mg of CBZ and1800mg of OXC and 1200 mg of CBZ for males. Conclusions CBZ and OXC are associated with cognitive impairment. Pharmacokinetic and pharmacodynamic differences are likely to be the reason for gender differences in reporting side effects. Potentially, females need to be prescribed lower dosages in view of their tendency to reach toxic levels at lower dosages. Side effects associated with AED could be a major reason for changing drugs or to consider a referral for surgical management

Ramipril and Risk of Hyperkalemia in Chronic Hemodialysis Patients

Angiotensin converting enzyme (ACE) inhibitors provide well known cardiorenal-protective benefits added to antihypertensive effects in chronic renal disease. These agents are underused in management of patients receiving hemodialysis (HD) because of common concern of hyperkalemia. However, few studies have investigated effect of renin angiotensin aldosterone system (RAAS) blockade on serum potassium in hemodialysis patients. We assessed the safety of ramipril in patients on maintenance HD. We enrolled 28 adult end stage renal disease (ESRD) patients treated by maintenance HD and prescribed them ramipril in doses of 1.25 to 5 mg per day. They underwent serum potassium concentration measurements before ramipril introduction and in 1 to 3 months afterwards. No significant increase in kalemia was found. Results of our study encourage the use of ACE inhibitors in chronically hemodialyzed patients, but close potassium monitoring is mandatory